A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
Phase 1
Completed
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Drug: GW679769 (Casopitant) oral tabletsDrug: Rifampin oral capsules
- Registration Number
- NCT00405080
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Treatment Period 1 GW679769 (Casopitant) oral tablets Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days. Treatment Period 2 GW679769 (Casopitant) oral tablets Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin. Treatment Period 2 Rifampin oral capsules Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
- Primary Outcome Measures
Name Time Method Plasma levels for casopitant will be measured in Period 1 at Day 1 to 3 and in Period 2 at Day 8. Plasma levels for rifampin will be measured in Period 2 at Day 8 to 10. Up to Day 10
- Secondary Outcome Measures
Name Time Method clinical lab tests adverse events vital signs 12 lead ECGs liver function tests Up to Day 12
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸Tacoma, Washington, United States